Anticancer plants: A review of the active phytochemicals, applications in animal models, and regulatory aspects
The rising burden of cancer worldwide calls for an alternative treatment solution. Herbal
medicine provides a very feasible alternative to western medicine against cancer. This …
medicine provides a very feasible alternative to western medicine against cancer. This …
Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement
S Altenhöfer, KA Radermacher… - Antioxidants & redox …, 2015 - liebertpub.com
Significance: Oxidative stress, an excess of reactive oxygen species (ROS) production
versus consumption, may be involved in the pathogenesis of different diseases. The only …
versus consumption, may be involved in the pathogenesis of different diseases. The only …
Celastrol: a review of useful strategies overcoming its limitation in anticancer application
J Shi, J Li, Z Xu, L Chen, R Luo, C Zhang… - Frontiers in …, 2020 - frontiersin.org
Celastrol, a natural bioactive ingredient derived from Tripterygium wilfordii Hook F, exhibits
significant broad-spectrum anticancer activities for the treatment of a variety of cancers …
significant broad-spectrum anticancer activities for the treatment of a variety of cancers …
Ferroptosis inducer erastin sensitizes NSCLC cells to celastrol through activation of the ROS–mitochondrial fission–mitophagy axis
M Liu, Y Fan, D Li, B Han, Y Meng, F Chen… - Molecular …, 2021 - Wiley Online Library
Despite recent progress in non‐small‐cell lung cancer (NSCLC) treatment, treatment
outcomes remain poor, mainly because of treatment resistance or toxicity. Erastin is a …
outcomes remain poor, mainly because of treatment resistance or toxicity. Erastin is a …
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives
D Chen, M Frezza, S Schmitt, J Kanwar… - Current cancer drug …, 2011 - ingentaconnect.com
Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the
treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib …
treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib …
Targeting drug chemo-resistance in cancer using natural products
Cancer is one of the leading causes of death globally. The development of drug resistance
is the main contributor to cancer-related mortality. Cancer cells exploit multiple mechanisms …
is the main contributor to cancer-related mortality. Cancer cells exploit multiple mechanisms …
Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis
X Ma, L Xu, AT Alberobello, O Gavrilova, A Bagattin… - Cell metabolism, 2015 - cell.com
Altering the balance between energy intake and expenditure is a potential strategy for
treating obesity and metabolic syndrome. Nonetheless, despite years of progress in …
treating obesity and metabolic syndrome. Nonetheless, despite years of progress in …
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
P D'arcy, S Brnjic, MH Olofsson, M Fryknäs… - Nature medicine, 2011 - nature.com
Ubiquitin-tagged substrates are degraded by the 26S proteasome, which is a multisubunit
complex comprising a proteolytic 20S core particle capped by 19S regulatory particles,. The …
complex comprising a proteolytic 20S core particle capped by 19S regulatory particles,. The …
Exosomal formulation enhances therapeutic response of celastrol against lung cancer
Abstract Celastrol (CEL), a plant-derived triterpenoid, is a known inhibitor of Hsp90 and NF-
κB activation pathways and has recently been suggested to be of therapeutic importance in …
κB activation pathways and has recently been suggested to be of therapeutic importance in …
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation …
Q Ping Dou, JA Zonder - Current cancer drug targets, 2014 - ingentaconnect.com
Over the past ten years, proteasome inhibition has emerged as an effective therapeutic
strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib …
strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib …